Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]-Plazomicin in Healthy Men
NCT03177278Phase 1Completed
- Sponsor
- Achaogen, Inc.
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plazomicin in complicated urinary tract infection (cUTI), sponsored by Achaogen, Inc. Primary endpoints: Sum of percent of total radioactivity recovered in urine and feces relative to the administered radioactive dose minus any radioactivity lost due to emesis at 15 days, Total radioactivity concentration equivalents in plasma and blood at 15 days and 1 more. Started Jun 2017; status: completed.
02
Drugs
plazomicin
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03177278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177278.